Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05610280 · ClinicalTrials.gov registry record · Phase 3
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
A Phase 3 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,478
- Enrollment target
NCT05610280: Completed Phase 3 study, sponsored by Ionis Pharmaceuticals.
NCT05610280 is a Phase 3 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 1,478 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05610280, a Phase 3 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,478 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia.
Interventions
- DRUG Placebo
- DRUG Olezarsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,478 participants |
| Start Date | 2022-11-21 |
| Est. Completion | 2025-06-09 |
| Phase | Phase 3 |
What the finished NCT05610280 record still lists
NCT05610280 is an interventional study that assigns participants to a tested intervention. Its 1,478 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05610280 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05610280 about?
NCT05610280 is a clinical study titled "A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia". The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia.
What is the current status of trial NCT05610280?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,478 participants. The study started on 2022-11-21. Estimated completion is 2025-06-09.
What interventions are being tested in trial NCT05610280?
The interventions under investigation include: Placebo (DRUG), Olezarsen (DRUG).
Who is sponsoring clinical trial NCT05610280?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05610280's enrollment target sits among peer trials
1,478 163rd of 2000 higher than 1,838 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05869552 · 1,485 participants · NA
Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI